CytoMed renames subsidiary for international push

CytoMed Therapeutics Limited reports that its wholly owned subsidiary Advance Cancer Centre Pte.

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reports that its wholly owned subsidiary Advance Cancer Centre Pte. Ltd., established in 2020, has been renamed CytoMed International Pte. Ltd., effective May 6, 2026. The new name is meant to reflect a stronger push into international markets.

The company plans to expand its footprint through overseas joint ventures, international medical tourism initiatives, and appointment of overseas representatives, with an initial focus on Asia, especially China, where its allogeneic gamma delta T cell technology is drawing partner interest following China’s Directive 818. The subsidiary currently holds a 19.0% equity interest in a licensed clinic in Malaysia and may increase this stake in the future. The name change does not alter the subsidiary’s legal entity, ownership structure, or contracts, and CytoMed intends to use internal resources to fund this international platform.

Key Figures

Effective date of name change: May 6, 2026 Equity interest in Malaysian clinic: 19.0% equity interest Subsidiary establishment year: 2020

3 metrics

Effective date of name change May 6, 2026 CytoMed International Pte. Ltd. name effective date

Equity interest in Malaysian clinic 19.0% equity interest Held by CytoMed International Pte. Ltd.

Subsidiary establishment year 2020 Year the wholly owned subsidiary was established

Key Terms

allogeneic gamma delta T cell technology, Directive 818, international medical tourism initiatives, joint ventures, +1 more

5 terms

allogeneic gamma delta T cell technology medical

"where the Company’s allogeneic gamma delta T cell technology is attracting interest from potential partners"

Directive 818 regulatory

"amidst China’s introduction of Directive 818 which clarifies the clinical pathways"

international medical tourism initiatives other

"development of international medical tourism initiatives, appointment of overseas representatives"

joint ventures financial

"including setting up joint ventures overseas, development of international medical tourism initiatives"

A joint venture is a business arrangement where two or more companies come together to work on a specific project or goal, sharing both the risks and the rewards. It’s like partners teaming up for a common goal, which can help them access new markets, share expertise, or reduce costs. For investors, joint ventures can create new opportunities but also involve shared responsibilities and potential risks.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

FAQ

What change did CytoMed Therapeutics (GDTC) announce in this 6-K filing?

CytoMed Therapeutics announced that its wholly owned subsidiary Advance Cancer Centre Pte. Ltd. has been renamed CytoMed International Pte. Ltd., effective May 6, 2026, to better reflect its international expansion strategy and overseas growth ambitions.

Why did CytoMed Therapeutics (GDTC) rename Advance Cancer Centre Pte. Ltd.?

The subsidiary was renamed to CytoMed International Pte. Ltd. to highlight a renewed focus on expanding internationally, including overseas joint ventures, international medical tourism initiatives, appointing overseas representatives, and strengthening the company’s profile in key foreign markets.

Which regions are the initial focus of CytoMed Therapeutics’ international expansion?

CytoMed’s initial international focus is in Asia, particularly China, where its allogeneic gamma delta T cell technology is attracting interest from potential partners amid China’s Directive 818, which clarifies clinical pathways for such therapies.

What assets does CytoMed International Pte. Ltd. currently hold for CytoMed Therapeutics (GDTC)?

CytoMed International Pte. Ltd.’s only asset at present is a 19.0% equity interest in a licensed clinic in Malaysia, and the company holds an option to increase its shareholding in that clinic in the future.

Does the subsidiary’s name change affect CytoMed Therapeutics’ legal or contractual arrangements?

The name change does not affect the subsidiary’s legal entity, ownership structure, or existing contractual obligations. It is a rebranding aligned with international growth plans rather than a change in legal or economic rights.

How will CytoMed Therapeutics (GDTC) fund its newly renamed international subsidiary?

CytoMed plans to use its internal resources to seed CytoMed International Pte. Ltd. while it develops joint ventures, international medical tourism initiatives, and other overseas activities aligned with its global expansion strategy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

The Company today announced that its wholly owned subsidiary established in 2020, Advance Cancer Centre Pte. Ltd., has changed its name to CytoMed International Pte. Ltd., effective May 6, 2026.

The name change reflects the Company’s renewed focus on expanding its international footprint, including setting up joint ventures overseas, development of international medical tourism initiatives, appointment of overseas representatives and enhancing its profile overseas. Initial geographical focus will be in Asia especially China where the Company’s allogeneic gamma delta T cell technology is attracting interest from potential partners amidst China’s introduction of Directive 818 which clarifies the clinical pathways.

The subsidiary’s only asset at present is a 19.0% equity interest in a licenced clinic in Malaysia, with an option to increase its shareholding in the future.

The name change does not affect the subsidiary’s legal entity, ownership structure, or existing contractual obligations.

Further information on our international plans will be provided once finalized. Meanwhile the Company will use its internal resources to seed this subsidiary.

For more information, please contact Evelyn Tan via email at investors@cytomed.sg or by telephone at +60127253505.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: May 11, 2026	Title:	Chairman and Director